Introduction
Electrolyte abnormalities are common in patients with chronic heart failure (CHF) and may affect treatment decisions and outcome. Hyponatraemia and both hypo-and hyperkalaemia are adverse prognostic markers that have been therapeutic targets in some recent trials. 1, 2 Hyponatraemia is a marker of severe CHF that might prompt consideration of a heart transplant. 3 Until very recently, the possible importance of serum chloride levels in patients with CHF had been overlooked. 
Hypochloraemia (<96 mmol/L) is common in patients with CHF
and is associated with a higher risk of mortality in patients with acute or chronic heart failure, independent of prognostic markers such as amino-terminal pro-B-type natriuretic peptide (NT-proBNP). 4 -10 It is not yet clear whether hypochloraemia has a direct pathological effect, 5, 8 or is merely a consequence of diuretic therapy, 11 or a marker of congestion and disease severity.
Information on the clinical and prognostic significance of abnormal serum chloride levels in unselected outpatients with heart failure with either reduced (HFrEF) or preserved ejection fraction (HFpEF) is lacking. Importantly, there are little data on the mode of death associated with abnormal chloride levels in patients with heart failure. We therefore investigated the prevalence and clinical and outcome associations of hyper-and hypochloraemia in a large cohort of ambulatory patients with HFrEF or HFpEF.
Methods

Patient population
Between September 2000 and October 2016, consecutive referrals (n = 6897) from both primary and secondary care were enrolled at a single secondary care clinic serving a local population of about 500 000 people (The Hull LifeLab). The study conforms to the principles outlined in the Declaration of Helsinki and was approved by relevant ethical bodies. All subjects gave their written informed consent. For the purpose of this analysis, CHF was defined as the presence of signs or symptoms consistent with the diagnosis and either left ventricular systolic dysfunction (LVSD) worse than mild, defined as HFrEF, or LVSD absent or at most mild and abnormal NT-proBNP plasma levels (>125 ng/L), defined as HFpEF.
Hypochloraemia, hyponatraemia and hypokalaemia were defined as greater than two standard deviations (SD) below the mean electrolyte level in the normal distribution for the local population (<96 mmol/L, <135 mmol/L, and < 3.5 mmol/L, respectively). Hyperchloraemia was defined as greater than two SD above the mean chloride level in the normal distribution for the local population (>105 mmol/L).
Outcomes
Patients were followed up until 16 October 2016. The primary outcomes of interest were all-cause mortality and the composite endpoint of mortality or hospitalisation with heart failure. For each patient who died, the cause of death was adjudicated as detailed in the online supplementary material.
Statistical analysis
Categorical data are presented as percentages, normally distributed continuous data are presented as mean ±SD and non-normally distributed variables are presented as median and interquartile range (IQR).
The relationship between chloride and other variables was assessed by Pearson correlation coefficients. Uni-and multivariable linear regression models were used to identify variables associated with serum chloride. Only variables with P < 0.05 in univariable analysis were included in the multivariable model. Log-transformed NT-proBNP was used.
Patients with CHF were divided as a whole and by phenotype (HFrEF or HFpEF) into chloride quartiles and groups depending on the presence of hyponatraemia and/or hypochloraemia: group 1 -hyponatraemia and hypochloraemia; group 2 -normal sodium and hypochloraemia; group 3 -hyponatraemia and normal chloride; and group 4 -normal sodium and chloride levels. Chi-squared tests were used to compare categorical variables, and one-way analysis of variance (ANOVA) was used to compare continuous variables across the groups, assumptions of ANOVA (normality or residuals and equal Associations between variables and outcome were assessed with Cox regression, proportionality of hazards was checked by residual plotting. Univariable analysis was conducted using all variables in the dataset and variables with P > 0.1 in univariable analysis or with more than 10% missing values (an arbitrary threshold) were not included in the multivariable analyses. Kaplan-Meier curves were used to demonstrate outcome by different groups.
Harrell's C-statistic (area under the receiver-operating characteristic curve) was used to highlight the discrimination of different outcome models with and without chloride. Twenty-five-fold cross validation was performed on all variables in the database.
Statistical analysis was carried out using the Stata 14 and SPSS 23 software packages. The two-tailed level of statistical significance was set at P < 0.05.
Results
Of the 6897 patients referred to the heart failure service, 5613 had data on echocardiography, NT-proBNP and serum chloride at baseline, 908 patients did not have heart failure and were not included in the analysis. Of the remaining 4705 patients ( Table 1) , 1988 patients had HFrEF (online supplementary Table S1 ) and 2717 patients had HFpEF (online supplementary Table S2 ).
The prevalence of hypochloraemia was 10.7% in patients with heart failure, 12.6% in patients with HFrEF and 9.3% in patients with HFpEF (P < 0.001). By comparison, the prevalence of hyponatraemia was 11.3% amongst all patients with heart failure, 13.1% in patients with HFrEF and 10.1% in patients with HFpEF (P = 0.002). The prevalence of dual hypochloraemia and hyponatraemia was 5.9% in all patients, 7.2% in patients with HFrEF and 5.0% in patients with HFpEF (P = 0.001). The prevalence of hyperchloraemia was 13.2% amongst all patients with heart failure, 11.7% in patients with HFrEF and 14.3% in patients with HFpEF (P = 0.001).
Patient characteristics by serum chloride levels
Median chloride of patients in the first quartile (Q1) was 96 mmol/L (range 76-99 mmol/L) and 106 mmol/L (range 104-117 mmol/L) in the fourth quartile (Q4).
Patients in Q1 [including those with hypochloraemia (<96 mmol/L)] were older, more likely to have atrial fibrillation or diabetes and had more severe symptoms and a higher rate of loop diuretic prescription compared to patients in Q2-Q4 (P < 0.001) ( Table 1) . Fifty-nine per cent of patients in Q1 who were taking loop diuretic were prescribed doses of ≥80 mg of furosemide per day ( Table 1) .
Patients with hypochloraemia had higher NT-proBNP than those with normal chloride levels (P < 0.001). There was a general trend towards higher NT-proBNP amongst patients in Q1 compared to Q2-Q4; the relationship was significant (P < 0.001) but weak (r 2 = 0.021; scatterplot not shown). By contrast, patients with hyperchloraemia (>105 mmol/L) were less likely to have severe symptoms and signs, had lower 73 (10) 71 (11) 7 2 ( 10)
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NT-proBNP and had a lower rate of diuretic prescription than patients with hypochloraemia or low-normal chloride (Q1 and Q2) (P < 0.001). Similar trends were observed across the quartiles in the HFrEF and HFpEF subgroups (online supplementary Tables S1 and S2). Median NT-proBNP was higher (1750 ng/L vs. 734 ng/L; P < 0.001), and the proportion of patients with New York Heart Association (NYHA) class III or IV symptoms (35% vs. 24%; P < 0.001) or taking a loop diuretic (75% vs. 54%; P < 0.001) was greater amongst patients with HFrEF compared to patients with HFpEF. Additionally, the proportion of patients with hypochloraemia who were taking a loop diuretic was higher in patients with HFrEF compared to patients with HFpEF (91% vs. 69%; P < 0.001).
Patient characteristics by serum chloride and sodium concentrations
Patients with hypochloraemia and either low (group 1) or normal (group 2) sodium had similar demographics and disease severity ( Table 2) . However, there were several biochemical differences between the two groups possibly identifying two distinct groups of patients with hypochloraemia. For example, patients with hypochloraemia and normal sodium had higher bicarbonate, haemoglobin, haematocrit and rate of hypokalaemia than patients with hypochloraemia and hyponatraemia (P < 0.001) ( Table 2 ). Haemoglobin and haematocrit were similar in those with hyponatraemia regardless of chloride levels (group 1 and 3) ( Table 2) .
Disease severity, NT-proBNP and rate of high dose diuretic prescription were lower in patients with normal chloride levels regardless of sodium levels (groups 3 and 4) compared to those with low chloride levels regardless of sodium levels (groups 1 and 2) (P < 0.001) ( Table 2 ).
Associations with serum chloride
In all patients with heart failure and in both the HFrEF and HFpEF subgroups, there was a strong positive correlation between chloride and sodium and a strong negative correlation with bicarbonate in multivariable analysis (online supplementary Figure  S1 ). In all patients with heart failure and in both the HFrEF and HFpEF subgroups, chloride had a weak negative correlation with log[NT-proBNP] in univariable analysis. However, log[NT-proBNP] was only associated with chloride after adjustment for other variables amongst patients with HFrEF (online supplementary Figure S1) ; the association was of borderline significance (correlation coefficient = -0.326; t-statistic = -2.81; P = 0.05). The strength and direction of other associations with serum chloride were similar between heart failure phenotypes. Low serum chloride was strongly and independently associated with increasing mortality (Figure 1 ) and all-cause mortality or heart failure hospitalisation in all patients with heart failure and in the HFrEF and HFpEF subgroups. Other independent predictors of all-cause mortality or all-cause mortality or hospitalisation with heart failure in both HFrEF and HFpEF were increasing age, increasing heart rate, severe symptoms (NYHA class III or IV), loop diuretic use, increasing log[NT-proBNP], increasing urea and decreasing albumin. No variable was an independent predictor of one endpoint but not the other.
Predictors of outcome
Variables that were independent predictors of outcome in patients with HFpEF and not HFrEF were male sex, decreasing haemoglobin and increasing potassium levels. Variables that were independent predictors of outcome in patients with HFrEF and not HFpEF were increasing bilirubin and the presence of ischaemic heart disease (IHD) (data not shown). However, neither haemoglobin, potassium, bilirubin or the presence of IHD were associated with outcome in all patients with heart failure (online supplementary Tables S3 and S4).
Chloride as a predictor of adverse outcome
With each unitary decrease in chloride, there was a 4% increase in mortality [hazard ratio (HR) 1.04, 95% confidence interval (CI) 1.02-1.06, P < 0.001] and a 3% increase in mortality or hospitalisation with heart failure (HR 1.03, 95% CI 1.02-1.05, P < 0.001) independent of age, sex, body mass index, systolic blood pressure, heart rate, diabetes, IHD, NYHA class, log[NT-proBNP], sodium, bicarbonate, calcium, potassium, haemoglobin, creatinine, urea, estimated glomerular filtration rate, albumin, alkaline phosphatase, alanine transferase, bilirubin, prescription of loop diuretics and CHF phenotype (HFrEF vs. HFpEF) (online supplementary Table S3 and S4). Patients in Q1 had around a two-fold increased risk of mortality compared to patients in Q4 (Figure 2 ).
There was a tendency for mortality to increase as chloride increased substantially above the normal range (>105 mmol/L). However, there were very few patients with very high chloride levels and, thus, the event rate was low. Patients in Q4 were at a slightly higher risk of adverse outcome compared to patients in Q3, but the association was not statistically significant.
Patients with hypochloraemia had a similar prognosis, regardless of whether sodium was low (group 1) or normal (group 2), and both groups had a markedly worse prognosis than patients with isolated low sodium (group 3) or those with both normal sodium and chloride (group 4) (Figure 3) . The unadjusted odds ratio for mortality for patients with hypochloraemia was 2.64 compared to 1.71 for patients with hyponatraemia.
In 25-fold cross validation using all variables listed in Table 1 , chloride featured in 22 models (88%) as a predictor of outcome. By comparison, sodium, potassium, bicarbonate and haemoglobin did not feature in any model. However, chloride did not add to the prognostic value of two models: 
Cause of death after one-year follow-up
Amongst the 4505 patients with follow-up data to 1 year, 11% died, 60% from cardiovascular causes ( Table 3) . Death due to terminal heart failure was more common for patients in Q1 (including those with hypochloraemia) compared to Q2-Q4. Sudden death was more common in Q4 compared to Q1-Q3 but the event rate was much higher in Q1 ( Similar trends were seen across the quartiles in the HFrEF and HFpEF subgroups, although mortality rate was higher in patients with HFrEF compared to HFpEF (12% vs. 9%) and cardiovascular death was a more common mode of death amongst patients with HFrEF compared to patients with HFpEF (69% vs. 52%) (online supplementary Table S5 ).
Sudden death was more common among patients with hypochloraemia (groups 1 and 2) compared to those with normal chloride levels and hyponatraemia (group 3) (online supplementary Table  S6 ). The proportion of sudden deaths was greatest in patients with normal chloride and sodium levels (group 4) but the event rate was low. (5) 6 (3) 5 (4) 6 (8) 4 (4) 4 (4) 15 ( 
Chloride and NT-proBNP
Previous studies have either not included NT-proBNP, 7,10 found no difference, 5, 6, 8, 9 or found only a weakly significant difference 4 in natriuretic peptides between patients with low and normal serum chloride concentrations. In a very large cohort, we found a significant but weak inverse relation between chloride and NT-proBNP; however, the two were not related when corrections were made for other variables. Hypochloraemia was an indicator of severe disease, regardless of heart failure phenotype, and both decreasing chloride and increasing NT-proBNP were strong independent predictors of an adverse outcome, suggesting that they are assessing different aspects of the heart failure syndrome.
Chloride and sudden death
Low serum chloride concentrations may have a stimulatory effect on a family of enzymes, with-no-lysine (WNK) kinases, 13, 14 which increase activity of Na + -K + -2Cl -(NKCC) and Na + -Cl -(NC) co-transporters. 15, 16 NKCC and NC co-transporters have a role in maintaining myocyte volume and pH. 17, 18 Dysregulation of myocyte intracellular pH is arrhythmogenic 19 and impairs contractility. 20 Furthermore, cardiac chloride channels are implicated in sino-atrial pacing 21 and arrhythmogenesis. 
Chloride and sodium
Hypochloraemia, regardless of sodium levels, was associated with higher risk of mortality and mortality or heart failure hospitalisation than isolated hyponatraemia. Sodium was not associated with adverse outcome after adjustment for other variables, including chloride. Monitoring serum sodium levels is recommended as an important prognostic marker in patients with heart failure, but it may be that chloride should have similar prominence in guidelines and clinical practice. Our results support the assertions of Ferreira et al. 10 that chloride should be assessed in the context of serum sodium levels. There seem to be two biochemical phenotypes:
1. In patients with hypochloraemia and hyponatraemia who have low haemoglobin, haematocrit and mean cell volume: in such patients, haemodilution may be an important contributor to biochemical abnormalities 23, 24 (group 1, Table 2 ). 2. In patients with hypochloraemia and normal sodium levels who have higher haemoglobin with higher bicarbonate and a higher rate of hypokalaemia: in such patients, hypochloraemia may be due to depletion 11, 25 (group 2, Table 2 ).
Figure 3
Kaplan-Meier curves for all-cause mortality in patients with heart failure and reduced or preserved ejection fraction divided by groups based on the presence of hypochloraemia and/or hyponatraemia. Group 1 -hypochloraemia and hyponatraemia; group 2 -hypochloraemia and normal sodium levels; group 3 -normal chloride levels and hyponatraemia; group 4 -normal chloride and sodium levels. Unadjusted hazard ratios for different groups compared to group 4 are also included.
Metabolic alkalosis is the most common acid-base disturbance in patients with heart failure, 26 and chloride depletion in the context of alkalosis is a well-recognised complication of diuretic treatment. 26, 27 Both phenotypes have similar prevalence and risk of adverse outcome but the distinction may have implications for treatment, especially considering a similar proportion of patients have clinical signs of congestion in the two groups: while increasing the dose of loop diuretic might be appropriate to treat haemodilution, diuretic might also cause or worsen hypochloraemia. Patients with CHF who are prescribed loop diuretic have a poorer prognosis than those not needing diuretic treatment. 28 Electrolyte abnormalities, such as hypochloraemia, may contribute to such findings. Acetazolamide, a carbonic anhydrase inhibitor that reduces bicarbonate and sodium re-absorption and increases chloride re-absorption in the proximal tubule, can increase chloride levels . whilst also having a diuretic action (a 'chloride-sparing' diuretic), and warrants further attention. 29 It is important to note that not all patients with hypochloraemia were taking a loop diuretic, suggesting that other aspects of the heart failure syndrome, such as haemodilution, can cause hypochloraemia. This was particularly the case in the HFpEF subgroup, perhaps a reflection of the difficultly of making a clinical diagnosis of heart failure in patients with a normal ejection fraction, leading to a lower rate of diuretic prescription.
Redefining the normal limits for serum chloride
The U-shaped relation between chloride and mortality shows a substantial increase in risk of death at chloride concentrations <100 mmol/L (Figure 1) . Redefining hypochloraemia as <100 mmol/L would undoubtedly increase the number of patients who might be declared suitable for 'chloride-sparing diuretics', such as acetazolamide, in future trials and clinical practice.
We did find that very high levels of chloride were associated with an adverse outcome. However, the absolute number of patients at the high end of the chloride distribution was small and the absolute number of events smaller, making it impossible to draw conclusions with certainty.
Limitations
The limitations of retrospective analyses apply to our study and confounding factors cannot be excluded. A substantial proportion of patients referred to our clinic was naïve to treatment; initiation or adjustments of current treatment might have led to improved electrolyte balance. Our data are a snapshot of a single time-point and no conclusions can be drawn on the importance of changing chloride levels over time. Data on urinary electrolyte concentrations are also missing, which would be useful in further delineating the different phenotypes of hypochloraemia. Some might not accept an NT-proBNP >125 pg/mL as diagnostic for HFpEF, although it is consistent with the recent European Society of Cardiology guidelines, 30 and diagnosis of HFpEF remains difficult in most cases.
Although we recorded cause of death in a carefully prescribed manner, we were not able to use autopsy data to confirm mode and cause of deaths.
Conclusion
Hypochloraemia is an important adverse prognostic marker in patients with CHF and sudden death is a common mode of death amongst patients with heart failure and low chloride levels. Whether chloride is a target for treatment is not clear and should be tested in future clinical trials. Conflict of interest: none declared.
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